Combining Histone Modification Therapy and Immune Checkpoint Inhibitors for Tumor Treatment

Jingning  Wang

doi:10.54097/xctrap38

Authors

Jingning Wang

DOI:

https://doi.org/10.54097/xctrap38

Keywords:

Forensic entomology, Molecular identification, Sarcophagidae, Calliphoridae.

Abstract

Histone modifications play a crucial role in chromatin packaging and gene regulation during cell development. Differentiated alterations in histone modifications have the potential to adjust gene expression patterns, affecting tumorigenesis and cancerogenesis. Immune checkpoint inhibitors are effective treatments for attacking tumors and cancer cells; they are able to block the binding of protein receptors, allowing for the destruction of malignant cells through T-cells or NK cells. By combining the two therapies, tumor growth is prevented, and T-cells can more effectively target the malignant cells, resulting in lower doses of immune checkpoint inhibitors and lower risks of autoimmune diseases. This review discusses existing histone modifications and their roles in solid tumor development to identify therapeutic drugs that can reorganize gene expression patterns. Furthermore, this review summarizes existing research on immune checkpoint inhibitors and how a combination of both techniques can lead to more effective treatments. Future research may focus on other epigenetic mechanisms that can be paired with immune checkpoint inhibitors to remove tumors. Studies may also research the effects of pairing histone modifications with other immunotherapies for cancer treatment.

Downloads

Download data is not yet available.

References

Information on: https://www.who.int/news-room/fact-sheets/detail/cancer

Information on: https://www.cancer.gov/about-cancer/understanding/statistics

Information on: https://seer.cancer.gov/report_to_nation/statistics.html

Information on: https://www.cdc.gov/genomics/disease/epigenetics.htm

Information on: http://www.whatisepigenetics.com/histone-modifications/

T.B. Nicholson, N. Veland, T. Chen, Chapter 3 - Writers, Readers, and Erasers of Epigenetic Marks, in: S.G. Gray (Ed.), Epigenetic Cancer Ther., Academic Press, Boston (2015) 31-66.

L. Randles, K.J. Walters, Ubiquitin and its binding domains, Front. Biosci. Landmark Ed., 17 (2012) 2140-2157.

V.G. Allfrey, R. Faulkner, A.E. Mirsky, Acetylation and methylation of histones and their possible role in the regulation of rna synthesis, Proc. Natl. Acad. Sci. U. S. A., 51 (1964) 786-794.

P. Gujral, V. Mahajan, A.C. Lissaman, A.P. Ponnampalam, Histone acetylation and the role of histone deacetylases in normal cyclic endometrium, Reprod. Biol. Endocrinol. 18 (2020) 84.

A.A. Lane, B.A. Chabner, Histone Deacetylase Inhibitors in Cancer Therapy, J. Clin. Oncol. 27 (2009) 5459-5468.

Y. Yang, M. Zhang, Y. Wang, The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy, J. Natl. Cancer Cent., 2 (2022) 277-290.

Information on: https://clinicaltrials.gov/

E.L. Greer, Y. Shi, Histone methylation: a dynamic mark in health, disease and inheritance, Nat. Rev. Genet. 13 (2012) 343-357.

D. Singh, K. Nishi, K. Khambata, N.H. Balasinor, Introduction to epigenetics: basic concepts and advancements in the field, in: T. Tollefsbol (Ed.), Epigenetics Reprod. Health, Academic Press, 2020. xxv-xliv.

T. Sun, Z. Liu, Q. Yang, The role of ubiquitination and deubiquitination in cancer metabolism, Mol. Cancer 19 (2020) 146.

Information on: https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html

Information on: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors

P. Dobosz, T. Dzieciątkowski, The Intriguing History of Cancer Immunotherapy, Front. Immunol. 10 (2019) 2965.

Information on: https://www.cancerresearch.org/treatment-types/immunomodulators

J.A. Marin-Acevedo, E.O. Kimbrough, Y. Lou, Next generation of immune checkpoint inhibitors and beyond, J. Hematol. Oncol.J Hematol Oncol, 14 (2021) 45.

L. Sun, Y. Su, A. Jiao, X. Wang, B. Zhang, T cells in health and disease, Signal Transduct. Target. Ther. 8 (2023) 1-50.

Information on: https://www.cancerresearchuk.org/about-cancer/treatment/immunotherapy/types/checkpoint-inhibitors